<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00514215</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000559667</org_study_id>
    <secondary_id>P30CA022453</secondary_id>
    <secondary_id>WSU-C-2795</secondary_id>
    <secondary_id>WSU-HIC-050304M1(R)F</secondary_id>
    <nct_id>NCT00514215</nct_id>
  </id_info>
  <brief_title>Cryotherapy and GM-CSF in Treating Patients With Lung Metastases or Primary Lung Cancer</brief_title>
  <official_title>Percutaneous Cryotherapy and Aerosolized GM-CSF for Pulmonary Metastases and Primary Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barbara Ann Karmanos Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Barbara Ann Karmanos Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Cryotherapy kills tumor cells by freezing them. Giving an injection of GM-CSF
      before cryotherapy and inhaling GM-CSF after cryotherapy may interfere with the growth of
      tumor cells and shrink the tumor. Giving cryotherapy together with GM-CSF may kill more tumor
      cells.

      PURPOSE: This phase II trial is studying how well giving cryotherapy together with GM-CSF
      works in treating patients with lung metastases or primary lung cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine whether percutaneous cryotherapy in combination with aerosolized sargramostim
           (GM-CSF) has any demonstrable immunologic effect in patients with pulmonary metastases
           or primary lung cancer.

        -  Determine whether any systemic immune response is detectable by the combination of
           cryotherapy as the antigen presentation source and GM-CSF as the immunologic adjuvant.

        -  Determine whether low morbidities will be maintained in patients treated with this
           regimen.

        -  Determine whether effective immunization is associated with a drop in CD4+, CD25+,
           LTP(TGF-β1)+, Tr cells as measured by flow cytometry or ELISPOT assay for
           TGF-β1-secreting cells.

      Secondary

        -  Determine clinical response (i.e., tumor control in the dominant masses undergoing
           cryotherapy or in other metastatic sites) as measured by CT criteria.

        -  Determine the toxicity of this regimen in these patients.

      OUTLINE: Patients undergo CT-guided core biopsy of a dominant lung mass and placement of at
      least 2 cryoprobes. Prior to initiating the freeze, patients receive an interstitial
      injection of sargramostim (GM-CSF) near the tumor. Patients then undergo percutaneous
      cryotherapy over 2 hours utilizing a freeze-thaw-freeze cycle. Beginning within 3 days of
      cryotherapy, patients receive aerosolized GM-CSF twice daily for 1 week. Beginning on day 32,
      patients may elect to undergo a second course of treatment as described above in the absence
      of disease progression or unacceptable toxicity.

      Patients undergo blood and tumor tissue collection at baseline and periodically during study
      for immunological correlative studies. Peripheral blood mononuclear cells isolated from blood
      samples are analyzed for antigen-specific CD4-positive or CD8-positive T-cell response by
      flow cytometry or by TGF-β1 ELISPOT assay to measure TGF-β1- secreting cells. Tumor cell
      lysates extracted from tumor samples are pulsed with autologous dendritic cells and analyzed
      by ELISPOT assay to measure T-cell reactivity in tumor specimens.

      After completion of study therapy, patients are followed at 6 and 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunologic Response as Measured by ELISPOT Assay and Flow Cytometry</measure>
    <time_frame>Days 1 &amp; 32</time_frame>
    <description>CT-guided biopsy &amp; Peritumoral GM-CSF</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Response as Measured by CT Criteria</measure>
    <time_frame>Days 1 &amp; 32</time_frame>
    <description>CT-guided biopsy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>Days 11, 32, 43, &amp; 63</time_frame>
    <description>CBC, sodium, potassium, BUN, serum creatinine, calcium, glucose, SGOT, Alk Phos, bilirubin, Electrolytes, Albumin (Alb), Alanine transaminase (ALT), Aspartate transaminase (AST), Alkaline phosphatase (ALP), Total bilirubin (TBIL), Direct bilirubin (Conjugated Bilirubin), Gamma glutamyl transpeptidase (GGT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune Function and Cancer-specific Response</measure>
    <time_frame>Days 1 &amp; 32</time_frame>
    <description>CT-guided biopsy &amp; Peritumoral GM-CSF</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Kidney Cancer</condition>
  <condition>Lung Cancer</condition>
  <condition>Metastatic Cancer</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Sargramostim, Flow Cytometry, Biopsy. Cryosurgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sargramostim-250 μg, inhaled, two times a day, on days 4-10 and days 36-42 Flow cytometry-Days 1 &amp; 32 Immunoenzyme technique-Days 1 &amp; 32 CT guided biopsy-Days 1 &amp; 32 Cryosurgery-Days 1 and 32</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim</intervention_name>
    <description>250 μg, inhaled, two times a day, on days 4-10 and days 36-42</description>
    <arm_group_label>Sargramostim, Flow Cytometry, Biopsy. Cryosurgery</arm_group_label>
    <other_name>GM-CSF (Granulocyte-Macrophage Colony Stimulating Factor)</other_name>
    <other_name>Leukine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>flow cytometry</intervention_name>
    <description>Days 1 &amp; 32</description>
    <arm_group_label>Sargramostim, Flow Cytometry, Biopsy. Cryosurgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunoenzyme technique</intervention_name>
    <description>Days 1 &amp; 32</description>
    <arm_group_label>Sargramostim, Flow Cytometry, Biopsy. Cryosurgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biopsy</intervention_name>
    <description>CT guided biopsy on days 1 &amp; 32</description>
    <arm_group_label>Sargramostim, Flow Cytometry, Biopsy. Cryosurgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>cryosurgery</intervention_name>
    <description>Days 1 and 32</description>
    <arm_group_label>Sargramostim, Flow Cytometry, Biopsy. Cryosurgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed diagnosis of 1 of the following:

               -  Primary non-small cell lung cancer (NSCLC)

                    -  Any stage nonoperative NSCLC or patient refuses surgery

               -  Any cancer with pulmonary metastatic disease (including renal cell cancer)

                    -  Stage IV disease (any T, any N, M1)

          -  Must have 1-10 pulmonary or mediastinal masses meeting the following criteria:

               -  At least 1 mass is appropriate for 2 sessions of core biopsy and cryotherapy with
                  relatively easy access/low risk in nonoperative patients (or those refusing
                  surgery)

               -  The two dominant masses are defined as either the largest and/or those that may
                  cause imminent morbidity from continued local progression, thereby potentially
                  benefiting from thoracic cryotherapy alone

               -  Optimal tumor size &gt; 1.0 cm

                    -  Dominant masses up to 6 cm in diameter may be considered if thorough
                       cryotherapy coverage can be anticipated with minimal additional treatment
                       morbidity

          -  Measurable disease, defined as tridimensional measurements of up to 6 different
             pulmonary or mediastinal masses ≥ 0.5 cm by CT scan

          -  No active pleural effusion that could be related to respiratory infection or requires
             further work-up

          -  No untreated and/or unstable brain metastases

        PATIENT CHARACTERISTICS:

          -  Karnofsky performance status 70-100%

          -  Life expectancy ≥ 12 weeks

          -  Granulocyte count ≥ 1,500/mm³

          -  Platelet count ≥ 50,000/mm³

          -  INR &lt; 1.5 (i.e., normal PT/PTT)

          -  Hemoglobin ≥ 8.0 g/dL

          -  Bilirubin ≤ 2 times upper limit of normal (ULN)

          -  AST ≤ 3 times ULN

          -  Satisfactory pulmonary function test as determined by supervising oncologist, thoracic
             surgeon, or pulmonologist

          -  Not pregnant or lactating

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No other active malignancy except nonmelanoma skin cancer or carcinoma in situ of the
             cervix

               -  Inactive history of cancer allowed if the patient has been disease-free for &gt; 2
                  years

          -  No serious medical or psychiatric illnesses that would preclude informed consent or
             limit survival to &lt; 12 wks

          -  No uncontrollable cough or inability to lie flat

          -  No New York Heart Association class III or IV heart disease

          -  No known immunodeficiency state

          -  No uncontrolled infection

          -  No uncontrolled coagulopathy or bleeding diathesis

          -  No advance directive that would prevent the investigator from treating the participant
             in the event of a complication occurring during or after the procedure

          -  No medical contraindication or potential problem that would preclude protocol
             compliance

        PRIOR CONCURRENT THERAPY:

          -  More than 4 weeks since prior biologic therapy

          -  More than 4 weeks since prior immunotherapy

          -  More than 4 weeks since prior filgrastim (G-CSF) or sargramostim (GM-CSF)

          -  More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)

          -  More than 4 weeks since prior radiotherapy

          -  More than 2 weeks since prior corticosteroids

          -  More than 1 week since prior parenteral antibiotics

          -  At least 1 week since prior aspirin or aspirin-like medications

          -  At least 3 days since prior warfarin, clopidogrel bisulfate, or similar compounds

          -  No concurrent GM-CSF other than study drug

          -  No concurrent G-CSF

          -  No concurrent radiotherapy

          -  No concurrent glucocorticosteroids

          -  No concurrent parenteral antibiotics

          -  No concurrent immunosuppressive agents

          -  No concurrent drugs that cause bleeding tendencies

          -  No other concurrent biologic therapy, immunotherapy, radiotherapy, or chemotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter J. Littrup, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Barbara Ann Karmanos Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201-1379</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2007</study_first_submitted>
  <study_first_submitted_qc>August 8, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2007</study_first_posted>
  <results_first_submitted>February 9, 2015</results_first_submitted>
  <results_first_submitted_qc>February 9, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 23, 2015</results_first_posted>
  <last_update_submitted>February 9, 2015</last_update_submitted>
  <last_update_submitted_qc>February 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Barbara Ann Karmanos Cancer Institute</investigator_affiliation>
    <investigator_full_name>Peter Littrup</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>lung metastases</keyword>
  <keyword>stage I non-small cell lung cancer</keyword>
  <keyword>stage II non-small cell lung cancer</keyword>
  <keyword>stage IIIA non-small cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <keyword>recurrent renal cell cancer</keyword>
  <keyword>stage IV renal cell cancer</keyword>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sargramostim, Flow Cytometry, Biopsy. Cryosurgery</title>
          <description>Sargramostim-250 μg, inhaled, two times a day, on days 4-10 and days 36-42 Flow cytometry-Days 1 &amp; 32 Immunoenzyme technique-Days 1 &amp; 32 CT guided biopsy-Days 1 &amp; 32 Cryosurgery-Days 1 and 32
sargramostim: 250 μg, inhaled, two times a day, on days 4-10 and days 36-42
flow cytometry: Days 1 &amp; 32
immunoenzyme technique: Days 1 &amp; 32
biopsy: CT guided biopsy on days 1 &amp; 32
cryosurgery: Days 1 and 32</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sargramostim, Flow Cytometry, Biopsy. Cryosurgery</title>
          <description>Sargramostim-250 μg, inhaled, two times a day, on days 4-10 and days 36-42 Flow cytometry-Days 1 &amp; 32 Immunoenzyme technique-Days 1 &amp; 32 CT guided biopsy-Days 1 &amp; 32 Cryosurgery-Days 1 and 32
sargramostim: 250 μg, inhaled, two times a day, on days 4-10 and days 36-42
flow cytometry: Days 1 &amp; 32
immunoenzyme technique: Days 1 &amp; 32
biopsy: CT guided biopsy on days 1 &amp; 32
cryosurgery: Days 1 and 32</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55" lower_limit="40" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Immunologic Response as Measured by ELISPOT Assay and Flow Cytometry</title>
        <description>CT-guided biopsy &amp; Peritumoral GM-CSF</description>
        <time_frame>Days 1 &amp; 32</time_frame>
        <population>Patients who had metastatic Renal Cell carcinoma</population>
        <group_list>
          <group group_id="O1">
            <title>Sargramostim, Flow Cytometry, Biopsy. Cryosurgery</title>
            <description>Sargramostim-250 μg, inhaled, two times a day, on days 4-10 and days 36-42 Flow cytometry-Days 1 &amp; 32 Immunoenzyme technique-Days 1 &amp; 32 CT guided biopsy-Days 1 &amp; 32 Cryosurgery-Days 1 and 32
sargramostim: 250 μg, inhaled, two times a day, on days 4-10 and days 36-42
flow cytometry: Days 1 &amp; 32
immunoenzyme technique: Days 1 &amp; 32
biopsy: CT guided biopsy on days 1 &amp; 32
cryosurgery: Days 1 and 32</description>
          </group>
        </group_list>
        <measure>
          <title>Immunologic Response as Measured by ELISPOT Assay and Flow Cytometry</title>
          <description>CT-guided biopsy &amp; Peritumoral GM-CSF</description>
          <population>Patients who had metastatic Renal Cell carcinoma</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67" lower_limit="35" upper_limit="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Response as Measured by CT Criteria</title>
        <description>CT-guided biopsy</description>
        <time_frame>Days 1 &amp; 32</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Toxicity</title>
        <description>CBC, sodium, potassium, BUN, serum creatinine, calcium, glucose, SGOT, Alk Phos, bilirubin, Electrolytes, Albumin (Alb), Alanine transaminase (ALT), Aspartate transaminase (AST), Alkaline phosphatase (ALP), Total bilirubin (TBIL), Direct bilirubin (Conjugated Bilirubin), Gamma glutamyl transpeptidase (GGT)</description>
        <time_frame>Days 11, 32, 43, &amp; 63</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immune Function and Cancer-specific Response</title>
        <description>CT-guided biopsy &amp; Peritumoral GM-CSF</description>
        <time_frame>Days 1 &amp; 32</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Sargramostim, Flow Cytometry, Biopsy. Cryosurgery</title>
          <description>Sargramostim-250 μg, inhaled, two times a day, on days 4-10 and days 36-42 Flow cytometry-Days 1 &amp; 32 Immunoenzyme technique-Days 1 &amp; 32 CT guided biopsy-Days 1 &amp; 32 Cryosurgery-Days 1 and 32
sargramostim: 250 μg, inhaled, two times a day, on days 4-10 and days 36-42
flow cytometry: Days 1 &amp; 32
immunoenzyme technique: Days 1 &amp; 32
biopsy: CT guided biopsy on days 1 &amp; 32
cryosurgery: Days 1 and 32</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Decreased Platelets ( thrombocytopenia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain (noncardiac, nonpleuritic)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Low grade fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pain at incision site</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic Reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Lymphopenia (low lever of lymphocytes)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Platelets (low count, thrombocytopenia)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Wall Pain</sub_title>
                <counts group_id="E1" events="12" subjects_affected="6" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Sensory Neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic Rhinitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Bronchospasm, wheezing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="12" subjects_affected="7" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hemoptysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hemorrhage, pulmonary lung (hemoptysis)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pain - Upper Respiratory throat</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Shortness of Breath</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small sample size.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Peter Littrup, M.D.</name_or_title>
      <organization>Barbara Ann Karmanos Cancer Institute</organization>
      <phone>313-576-8758</phone>
      <email>littrupp@karmanos.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

